High frequency oscillatory ventilation (HFOV) was first described in 1959. It has had variable uptake in critical care with greater use in neonatal and paediatric intensive care units (ICU) than in adults 1 . In this issue, Boots et al 2 describe the use of HFOV across a wide spectrum of patients with severe respiratory failure due to pandemic H1N1 influenza. Units from across Australia and New Zealand contributed data regarding patients admitted during the pandemic. The fact that there is an established network and organisational structure for the study of intensive care outcomes in Australia and New Zealand facilitated the rapid mobilisation of resources to gather data on the intensive care effects of the pandemic, and those involved should be congratulated. Other data on the impact of pandemic H1N1 on Australian ICUs in 2009 have already been published 3 .
Though numbers in the Boots et al paper are small, the results are both interesting and instructive. Fifty patients receiving HFOV were studied. Of these 22 were proven to have H1N1, representing about 3% of all patients admitted to ICUs with H1N1 associated respiratory failure. Seventy-seven percent of the H1N1 cohort survived. The high survival rate in this severely ill cohort of patients is impressive, as are the sustained improvement in oxygenation indices in these patients. How this relates to an improvement in survival compared with conventional ventilation is hard to judge. These patients were considered to require a rescue mode of ventilation, often already had other rescue therapies underway, and this was in no way a randomised trial, rather a detailed observational study. Prior trials on the use of HFOV in adults with severe lung disease 4,5 and routine use in neonates 6 have not shown significant survival advantages over conventional ventilation, though a recent meta-analysis 1 challenges this. That survival was comparable in this cohort to the group treated with extracorporeal membrane oxygenation (ECMO), and that only two of the H1N1 HFOV patients were subsequently referred for rescue ECMO is tantalising: HFOV is less resource intensive and could be considered potentially more widely applicable. Nine percent of patients with severe respiratory failure during the H1N1 pandemic of 2009 were treated with ECMO. The question remains as to whether HFOV may have averted some of the requirement for this resource.
Patients with severe respiratory failure due to other causes treated with HFOV had lower survival. With small numbers excessive inference cannot be made from this as the authors have pointed out. Children were commenced on HFOV with lesser indices of lung disease compared with adults. This perhaps reflects the typically lower threshold to deploy HFOV in the PICU and greater relative experience in its use.
One of the criticisms of HFOV by clinicians, and a hot topic of debate at least within my own department, is an apparently high rate of barotrauma, substantiated in some of the literature 4, 5 . In this cohort, barotrauma occurred with equal frequency before and after initiating HFOV, suggesting the issue relates to pathology and broader aspects of therapy, rather than mode of ventilation per se.
No detailed data are available regarding quality of life in the survivors from this HFOV cohort. The overwhelming majority of patients were ambulant, with relatively normal room air saturation on hospital discharge; useful data but worthy of further study to assess quality of life after survival of severe acute lung disease.
The prospect that reversible severe lung disease, for which H1N1 is but one example, can be treated effectively using this mode of ventilation is worthy of clinical consideration at present, and invites the question of a larger trial in the near future.
It is notable that most units involved in this study held only one oscillator. Arguably, holding only a single device for any particular therapy will limit clinician exposure and render a unit vulnerable to device failure at a critical time. For units in which there is a view that HFOV is a useful therapy and will form the basis of respiratory rescue, the procurement of two units should be considered.
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Anaesthesia and Intensive Care, Vol. 39, No. 5, September 2011 The paper from Boots and co-workers contributes not only to our knowledge of the use of (and the issues around) HFOV in units faced with the H1N1 pandemic, but also gives cause to reflect on the potential of HFOV for other uses in adults as well as areas for further study. Whether units using HFOV should form a case registry with a standardised dataset, as has been done for ECMO, is a question that should be brought to those units undertaking HFOV in adults. This would permit numerically large analyses in the absence of randomised trials. With a paucity of high quality randomised trial data on the management of severe acute respiratory failure with failure of conventional ventilation, clinicians remain forced to use therapies for which there is a seriously limited evidence base, and we remain at the level of rationale-based medicine.
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